RESCHEDULED: Real-World CAR-T Data Update

Name: RESCHEDULED: Real-World CAR-T Data Update
Start: 2024-03-18T13:00:00-04:00
End: 2024-03-18T14:00:00-04:00

RESCHEDULED: Real-World CAR-T Data Update

Immunotherapy (CAR T, Bispecifics and more) Treatment

Mar 18, 2024 / 01:00PM - 02:00PM EDT

Event Description

Myeloma patients and their loved ones have been learning about the novel CAR-T therapies that are significantly improving myeloma care. A lot of the information we have comes from clinical trials. What are we learning in the clinic about CAR-T, including how older patients are responding, what long-term side effects look like, and more?

Come with your questions and get ready to learn with us!

Schedule & Agenda

Introductions

1:00 PM

Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Sham Mailankody, MBBS.

1 :00 PM

Audrey Burton-Bethke

Introductions

Audrey introduces the agenda of the event and featured speaker Sham Mailankody, MBBS.

Presentation

1:05 PM

Sham Mailankody, MBBS

Dr. Sham Mailankody discusses how real-world data is informing us about novel CAR-T therapies.

1 :05 PM

Sham Mailankody, MBBS

Presentation

Dr. Sham Mailankody discusses how real-world data is informing us about novel CAR-T therapies.

Questions and Answers

1:35 PM

Audience

Type your questions in the chat and we will answer them!

1 :35 PM

Audience

Questions and Answers

Type your questions in the chat and we will answer them!

Speakers & Moderators

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio

Sham Mailankody, MBBS

I am a medical oncologist specializing in the care of people with multiple myeloma and related plasma cell disorders. With my colleagues at Memorial Sloan Kettering Cancer Center (MSK), I am focused on identifying optimal treatment strategies for people with these disorders. My research focuses on the development of novel immune and cellular therapies, including chimeric antigen receptor (CAR) T cell therapies, for patients with myeloma. I also serve as the Clinical Director of the Cellular Therapy Service and the Research Director of the Myeloma Service at MSK.

Read Bio